Use of a single-capsule 17β-estradiol (E2)/progesterone (P4) to treat vasomotor symptoms does not appear to produce unwanted changes in body weight and blood pressure (BP) in postmenopausal women, according to data from the phase III REPLENISH trial.
A paclitaxel-carboplatin (PCb) regimen may be an alternative adjuvant chemotherapeutic strategy for women with operable triple-negative breast cancer (TNBC), given its greater benefit over a conventional regimen comprising cyclophosphamide, epirubicin, and fluorouracil, followed by docetaxel (CEF-T), the phase III PATTERN* trial has shown.
Shorter reproductive years and greater parity appear to increase the risk of cognitive impairment in late life among Singaporean Chinese women, while the use of oral contraceptives and hormone-replacement therapy (HRT) may reduce such risk, according to a study.
Use of a levonorgestrel intrauterine device (IUD) can help reduce menstrual bleeding in adolescents with disabilities — thus providing an option for menstrual management in this population with special needs, in whom data on IUD use are lacking.
Endometrial scratching prior to first cycle of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) has no benefit on livebirth or clinical pregnancy rate, according to a study presented at ESHRE 2020.
The local incidence of difficult intubation of patients delivering by caesarean section under general anaesthesia at a high-volume obstetric hospital in Singapore is 33 in 660 (1:20 or 5.0 percent), reports a recent study. No case of failed intubation has been recorded.
Yearly mammography starting from the age of 40 rather than the age of 50 significantly reduces the risk of dying from breast cancer, particularly during the first 10 years of follow-up, according to the large randomized UK Age trial.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.